STING1 and breast carcinoma: It has been demonstrated in breast cancer and NSCLC that treatment with PARP inhibitors enhances expression of PD-L1 by increasing cytosolic DNA and consequently activating the cyclic GMP-AMP synthase (CGAS)/stimulator of interferon genes (STING) innate immune signaling.